New mechanism of action for class of chemotherapy drugs uncovered – 1
Narrator: This is NIH Health Matters, I’m Joe Balintfy. Researchers have uncovered new details on how a class of chemotherapy drugs works.
Pommier: PARP inhibitors have been found to be very promising for patients who suffer from predisposition because of BRCA, breast cancer-associated gene mutations.
Narrator: Dr. Yves Pommier is with the NIH’s National Cancer Institute.
Pommier: So there’s a great interest because these patients their tumors was not responsive usually to most therapies and they turn out to be selectively sensitive to these PARP inhibitors. So that’s the big interest and there are many drugs in the pipeline today.
Narrator: For more on this study and new cancer research, visit www.cancer.gov.Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.